Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comments On US FDA OTC Hearing Aid Proposed Rule Urge Clarification On Recommended Users

Executive Summary

More than 1,000 comments were submitted by professional and civic organizations, trade groups and consumers FDA proposed rule on allowing OTC sales of hearing aids intended for consumers with mild to moderate hearing loss.

You may also be interested in...



No Prescription? No Problem: FDA Draft Rule Gives Green Light To OTC Hearing Aids

The US FDA’s proposed reg, released on 19 October, aims to get more hearing aids into the ears of those who need them by allowing the devices to be purchased over the counter.

Perrigo Starts Supply Chain Overhaul After Filing OTC Birth Control NDA, Launching Nasonex Switch

Along with Q2 results including reported net sales up 14.3% to $1.12bn, Perrigo announces overhaul of its supply chain expected to generate $100m to $300m in net cost savings and creation of women's health, skin care business units.

Along With Sales Across Regions And Categories, Perrigo’s Labor Shortage Concerns Grow

“The only thing that keeps me up at night right now is labor shortages,” says CEO Murray Kessler. He also notes growing trend of consumers responding to inflation by moving from national brands to lower-priced private label/store brand OTC drugs.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel